--- title: "Keros Therapeutics (KROS) news: merger, layoffs and buyback" url: "https://aibio.space/companies/keros-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "KROS merger, layoffs and buyback news: Keros Therapeutics starts tender offer for up to 10,950,165 shares at $17.75. Keros Therapeutics, Inc." --- KROS Keros Therapeutics, Inc. NASDAQ · United States # Keros Therapeutics (KROS) news KROS merger, layoffs and buyback news Financings · 2026-09-08 ## [Keros Therapeutics authorizes $5 million share buyback after $20 million Takeda milestone](https://aibio.space/news/keros-therapeutics-authorizes-5-million-share-buyback-after-20-million/) The board approved the program after Keros received a development milestone payment under its elritercept license with Takeda. The program does not oblige Keros to buy any shares. ## Latest Keros Therapeutics news 1. 2025-10-20 Financings [Keros Therapeutics starts tender offer for up to 10,950,165 shares at $17.75](https://aibio.space/news/keros-therapeutics-starts-tender-offer-up-10-950-165-shares-17-75/) Keros Therapeutics, Inc. offers to buy back its stock for cash, for up to $194.4 million in total. The Schedule TO was filed October 20, 2025. 2. 2025-10-15 Mergers [Keros Therapeutics to repurchase 10,176,595 shares for about $181 million, plans tender offer](https://aibio.space/news/keros-therapeutics-repurchase-10-176-595-shares-about-181-million/) Keros Therapeutics agreed on October 15, 2025 to buy 10,176,595 shares from two investors for about $181 million at $17.75 each, and plans a tender offer for up to $194 million at the same price. Two directors resigned under the Pontifax agreement, and the company's preliminary cash figure of about $693.5 million is unaudited. 3. 2025-10-15 Mergers [Keros agrees to buy back ADAR1 and Pontifax shares at $17.75, plans tender offer](https://aibio.space/news/keros-agrees-buy-back-adar1-pontifax-shares-17-75-plans-tender-offer/) The repurchases are part of a $375 million capital return program. Keros also plans to share 25% of certain net cash from its Takeda license with stockholders. 4. 2025-05-29 Distress [Keros Therapeutics plans workforce reduction of approximately 45% in restructuring](https://aibio.space/news/keros-therapeutics-plans-workforce-reduction-approximately-45-percent/) Keros's board approved a plan on May 28, 2025 to cut its overall workforce by about 45%, with about $3.2 million in severance charges and up to about $0.4 million in retention costs. The cuts follow the January 2025 early termination of the PAH trial over pericardial effusion events, though the company held $559.9 million in cash at the end of 2024. 5. 2025-05-29 Distress [Keros Therapeutics drops cibotercept in PAH, cuts about 45% of staff](https://aibio.space/news/keros-therapeutics-drops-cibotercept-pah-cuts-about-45-percent-staff/) Headcount will fall to 85 full-time employees, with average annualized savings of about $17 million. The strategic alternatives review is still under way. ## Keros Therapeutics at a glance - **Ticker**: KROS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $257.6 million ### Related companies - [LB Pharmaceuticals](https://aibio.space/companies/lb-pharmaceuticals/) NASDAQ: LBRX - [Semnur Pharmaceuticals](https://aibio.space/companies/semnur-pharmaceuticals/) OTC: SMNR - [RISING BIOSCIENCES INC](https://aibio.space/companies/rising-biosciences/) OTC: RBII - [Tenaya Therapeutics](https://aibio.space/companies/tenaya-therapeutics/) NASDAQ: TNYA - [Tonix Pharmaceuticals Holding](https://aibio.space/companies/tonix-pharmaceuticals/) NASDAQ: TNXP - [Cocrystal Pharma](https://aibio.space/companies/cocrystal-pharma/) NASDAQ: COCP - [Minerva Neurosciences](https://aibio.space/companies/minerva-neurosciences/) NASDAQ: NERV - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT ### Also on NASDAQ - [STAAR SURGICAL CO](https://aibio.space/companies/staar-surgical/) STAA - [Baird Medical Investment Holdings](https://aibio.space/companies/baird-medical-investment/) BDMD - [AquaBounty Technologies](https://aibio.space/companies/aquabounty-technologies/) AQB - [MDxHealth SA](https://aibio.space/companies/mdxhealth/) MDXH - [Intensity Therapeutics](https://aibio.space/companies/intensity-therapeutics/) INTS - [Caris Life Sciences](https://aibio.space/companies/caris-life-sciences/) CAI ## Keros Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$243.9 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | [$0](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | | Research and development | [$129.6 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | [$173.6 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | | Net income (loss) | [$87.0 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | [-$187.4 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | | Cash from operations | [$107.5 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | [-$160.9 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | | Cash and equivalents | [$287.4 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000049/) | [$559.9 million](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000018/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $257.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Keros Therapeutics Is Keros Therapeutics involved in a merger or acquisition? Our latest story on this, dated Oct 20, 2025: "Keros Therapeutics starts tender offer for up to 10,950,165 shares at $17.75". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/keros-therapeutics-starts-tender-offer-up-10-950-165-shares-17-75/). Has Keros Therapeutics cut staff? Our latest story on this, dated May 29, 2025: "Keros Therapeutics drops cibotercept in PAH, cuts about 45% of staff". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/keros-therapeutics-drops-cibotercept-pah-cuts-about-45-percent-staff/). Does Keros Therapeutics have a share buyback? Our latest story on this, dated Sep 8, 2026: "Keros Therapeutics authorizes $5 million share buyback after $20 million Takeda milestone". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/keros-therapeutics-authorizes-5-million-share-buyback-after-20-million/). What is the ticker symbol of Keros Therapeutics? Keros Therapeutics, Inc. trades under the ticker KROS on NASDAQ. Where is Keros Therapeutics listed? Keros Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Keros Therapeutics? The SEC Central Index Key (CIK) for Keros Therapeutics, Inc. is 1664710. Its filings are on SEC EDGAR. How many shares does Keros Therapeutics have outstanding? 19,827,188 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-08-03. Which country or territory is Keros Therapeutics listed under? Our directory records Keros Therapeutics, Inc. under United States. What does Keros Therapeutics do? Our directory classifies Keros Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Keros Therapeutics? The ISIN recorded for Keros Therapeutics, Inc. is US4923271013. Does aibio.space cover Keros Therapeutics? aibio.space lists Keros Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What was Keros Therapeutics's revenue last year? $243.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Keros Therapeutics profitable? Keros Therapeutics, Inc. reported net income of $87.0 million for the fiscal year ended Dec 31, 2025, and generated $107.5 million of cash from operations, per its annual report to the SEC. How much does Keros Therapeutics spend on research and development? $129.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Keros Therapeutics have? $257.6 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Keros Therapeutics Members talk about Keros Therapeutics (KROS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Keros Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-08 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/exhibit9919826pr.htm) 2. 2025-10-20 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1664710/000110465925100554/tm2528628-1_sctoi.htm) 3. 2025-10-15 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1664710/000110465925099512/tm2528773d1_ex99-1.htm) 4. 2025-05-29 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/exhibit99152925pr.htm) 5. 2025-04-10 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1664710/000166471025000033/exhibit99141025pr.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KROS on TradingView](https://www.tradingview.com/symbols/NASDAQ-KROS/). ## SEC filings and registration - **SEC name**: Keros Therapeutics, Inc. - **CIK**: 1664710 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: KROS (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421 - **Phone**: 617-314-6297 - **Shares outstanding**: 19,827,188 as of 2026-07-27 (10-Q filed 2026-08-03) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000059/kros-20260929.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/kros-20260928.htm) filed 2026-09-28 - [S-3](https://www.sec.gov/Archives/edgar/data/1664710/000162828026061321/keros-sx3september2026.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/kros-20260908.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000050/kros-20260803.htm) filed 2026-08-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000049/kros-20260630.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/kros-20260803.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000043/kros-20260730.htm) filed 2026-07-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001664710), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Keros Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KROS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Keros Therapeutics, Inc. - **Ticker**: KROS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US4923271013 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KROS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/keros-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Keros Therapeutics (KROS) news: merger, layoffs and buyback", 2026-10-31, https://aibio.space/companies/keros-therapeutics/